In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Congress created business development companies in 1980 to support job growth and help emerging companies raise funds. As of 2023, there were 139 BDCs with $312 ...
The Vanguard board expects to add two new independent directors in early 2025 to fill seats that will be vacated when two long-serving independents retire. The ...
The bottom line: In the near term, it’s not likely that the roles and activities of mutual fund directors will change much. There will be no ...
The Securities and Exchange Commission this week said it found "deficiencies" and "weaknesses" in mutual funds' governance practices during examinations over the past four years. The ...